Changes In Serum Glucose Levels Research Articles

Stress and recovery of yellowtail kingfish (Seriola aureovittata) during Sea-land relay transportation: Biochemical, microecological and transcriptomic responses

Sea-land relay transportation (SRT) is a key part of the “land-based greenhouse + offshore net cage” mariculture system for yellowtail kingfish. In this study, the physiological status of yellowtail kingfish during SRT was assessed by determining serum biochemical indexes (levels of cortisol, glucose, and malondialdehyde (MDA), and activities of superoxide dismutase (SOD) and catalase (CAT)), the composition of intestinal microflora, and the liver transcriptome before (control), during, and after transportation (T1 and T2) and after recovery for 6 hours (6 h), 12 hours (12 h), 1 day (D1), 3 days (D3), and 7 days (D7). The results show that the serum cortisol and glucose levels, MDA level, and activities of SOD and CAT significantly increased during transportation, and decreased to similar levels to those in the control after 1 day of recovery. Bacteria including Acinetobacter, Enterobacter, and Comamonas accounted for more than 91 % of the microbial community in the gut of yellowtail kingfish, and these genera were associated with changes in serum glucose levels, indicating that they may help to alleviate the effects of transportation stress. Analyses of liver transcriptome data showed that significantly differentially expressed genes (DEGs) in the T2, D1, D3 and D7 groups were significantly enriched in the “Protein processing in the endoplasmic reticulum (ER)” pathway. At the end of transportation (T2 group), the ER-associated degradation (ERAD) pathway was activated, with up-regulation of hsp40, hsp70, and hsp90α. The transcript levels of these genes gradually returned to levels similar to those in the control during the recovery period. At the first day of recovery, the unfolded protein response imposed stress upon the ER, accompanied by significant down-regulation of PEPK and Calmin and significant up-regulation of CRT. The DEGs in the D3 group were enriched in the “ER”, “Steroid biosynthesis”, “Fatty acid degradation”, “PPAR signaling”, and “Fat digestion and absorption” pathways, whereas the number of DEGs related to lipid metabolism and stress pathways was significantly decreased in the D7 group. Our results indicate that hsp70 and hsp90α can be used as stress markers, and hsp40 can be used as a physio-metabolic recovery marker for yellowtail kingfish. These results show that, although serum indices recovered 24 hours after transportation, up to 3 days after transportation is an important period for recovery from transportation stress at the transcriptome level. “Protein processing in the ER pathway” is an important pathway regulating stress and recovery in yellowtail kingfish.

Neuroprotective Effect of Chlorogenic Acid in an Animal Model of Sporadic Alzheimer's Disease Induced by Streptozotocin.

Alzheimer's Disease is a degenerative neurological condition which leads to a decline in memory and cognitive function. Chlorogenic Acid (CGA) presents properties including neuroprotective, antioxidant and anti-inflammatory. The aim of this study was to examine the impact of CGA on cognitive impairments, neuroinflammation and neuronal damage in mice submitted to an experimental model of Sporadic Alzheimer Disease (SAD) induced by intracerebroventricular administration of streptozotocin (ICV-STZ). Male Swiss mice received bilateral ICV-STZ injections (3mg/Kg) on days 1 and 3. The treatment with CGA (5mg/Kg, orally) or vehicle (water, orally), was initiated and continued for 26days, starting 2h after the second induction procedure. At first, there was no change in serum glucose levels after SAD induction. ICV-STZ induces impairments in aversive, recognition, and spatial memory, while CGA treatment significantly alleviated these memory deficits. Furthermore, locomotor activity, working memory, and anxiety-related activities remained unaffected by the treatments. CGA treatment protects against ICV-STZ-induced increase in the nitrite/nitrate and TBARS levels. ICV-STZ induced a reduction in viable cells, depletion of BDNF, and triggered astrogliosis and microgliosis in the cortex and hippocampus. Treatment with CGA preserves viable cell count in the prefrontal cortex, CA1, and CA3 regions of the hippocampus. Additionally, it prevented BDNF depletion in the prefrontal cortex and hippocampus (CA1, CA3, and DG regions), and mitigated astrogliosis and microgliosis in the prefrontal cortex and hippocampus (CA1, CA3, and DG regions). These findings indicate the neuroprotective effects of CGA, underscoring their potential as therapeutic agents or adjuncts in the treatment of SAD.

Impact of Serum Glucose Levels on Outcomes in Acute Pancreatitis: A Retrospective Analysis.

Background and Objectives: The risk of developing glycemic dysregulation up to overt diabetes mellitus (DM) after an episode of acute pancreatitis (AP) is increasingly being analyzed. We aimed to assess the changes in serum glucose levels associated with the first episode of AP, as well as the impact of dysglycemia on outcomes such as the severity of inflammation, the length of hospitalization, mortality, and the persistence of hyperglycemia at follow-up. Materials and Methods: All patients experiencing their first episode of AP, who presented to the Emergency Room (ER) between 1 January 2020 and 31 December 2023, were retrospectively included. On-admission serum glucose and peak serum glucose during hospitalization were the biological markers used to assess glucose metabolism impairment, and they were correlated with outcomes of AP. Results: Our study included 240 patients, 46.67% (112 patients) having a biliary etiology for an AP flare. Patients with COVID-19-associated AP exhibited the highest on-admission and peak serum glucose levels (244.25 mg/dL and 305.5 mg/dL, respectively). A longer hospital stay was noted in patients with peak serum glucose levels of ≥100 mg/dL (9.49 days) compared to normoglycemic patients (6.53 days). Both on-admission and peak glucose levels were associated with elevated CRP levels during hospitalization. A total of 83.78% of patients who received antibiotics exhibited on-admission hyperglycemia, and 72.07% had peak serum glucose levels of ≥100 mg/dL. The presence of hyperglycemia at follow-up was associated with both on-admission and peak serum glucose levels of ≥100 mg/dL, as well as with a longer stay, higher CRP levels, and antibiotic use during index admission. Conclusions: On-admission hyperglycemia predicts a higher inflammatory response in patients at the first episode of AP, while the presence of hyperglycemia during hospitalization is associated with imaging and biological severity and longer hospitalizations, indicating a more severe disease course. Both on-admission and peak in-hospital hyperglycemia were identified as risk factors for sustained hyperglycemia at follow-up.

Association of a Single-Nucleotide Variant rs11100494 of the NPY5R Gene with Antipsychotic-Induced Metabolic Disorders.

Background: The usage of antipsychotics (APs) is the most robust and scientifically based approach in the treatment of schizophrenia spectrum disorders (SSDs). The efficiency of APs is based on a range of target receptors of the central nervous system (CNS): serotoninergic, dopaminergic, adrenergic, histaminergic and cholinergic. Metabolic disorders are the most severe adverse drug reactions (ADRs) and lead to cardiovascular diseases with a high rate of mortality in patients with SSDs. Neuropeptide Y receptor Y5 (NPY5R) is known in the chain of interaction to target receptors for APs, agouti-related peptide receptors and proopiomelanocortin receptors. We studied the association of the single-nucleotide variants (SNVs) rs11100494 and rs6837793 of the NPY5R gene, and rs16147, rs5573, rs5574 of the NPY gene, with metabolic disorders in Russian patients with SSDs. Methods: We examined 99 patients with SSDs (mean age—24.56 years old). The mean duration of APs monotherapy was 8 weeks. The biochemical blood test included levels of glucose, cholesterol, lipoproteins, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein and albumin. Anthropometry included weight, height, waist circumference and hip circumference. We used real-time PCR to study the carriage of major and minor alleles of the SNV rs11100494 (1164C>A) of the NPY5R gene (chromosome localization—4q32.2). Group 1 comprised 25 patients with SSDs taking APs with a change in body weight of more than 6% since the start of APs therapy. Group 2 comprised 74 patients with SSDs taking APs with a change in body weight of less than 6% since the start of APs therapy. Results: We show the significance of genetic risk factors (carriage of major allele C of SNV rs11100494 of the NPY5R gene) for the development of AP-induced weight gain in Russian patients with SSDs. The allele C predisposes to AP-induced weight gain (OR = 33.48 [95% CI: 12.62; 88.82], p-value < 0.001). Additionally, the results of our study demonstrate that first-generation APs (FGAs) are more likely to cause an increase in serum transaminase levels but are less likely to increase body weight. Second-generation APs (SGAs) are more likely to cause weight gain and changes in serum glucose levels. Conclusion: Our study shows the predictive role of the allele C of SNV rs11100494 of the NPY5R gene in the development of AP-induced weight gain. However, we did not find a significant association between biochemical markers and this SNV in Russian patients with SSDs.

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats.

Background: Thymoquinone (TQ) is a safe nutrient isolated from the seeds or volatile oil extract of Nigella sativa. In addition to its benefits in glucose regulation, TQ improves feeding disorders in diabetic animals. Glucagon-like peptide-1 (GLP-1) analogs improve glycemic control and ameliorate obesity or hyperphagia. Therefore, the present study aimed to investigate the role of GLP-1 in TQ-induced anorexia.Method: Type 2 diabetes was induced in rats by nicotinamide and streptozotocin injection. TQ was orally administered to diabetic rats at different doses for 45 days. Following TQ treatment, changes in serum glucose levels, GLP-1 concentration, body weight, food intake, and water intake were determined. To further explore the interaction between GLP-1 and TQ, the inhibitor of dipeptidyl peptidase 4, sitagliptin and the GLP-1 receptor antagonist exendin 9–39 (Ex 9–39) were separately administered to TQ- or vehicle-treated diabetic rats.Results: TQ treatment attenuated hyperglycemia and reduced hyperphagy and water intake in streptozotocin-induced diabetic rats in a dose-dependent manner. Moreover, TQ treatment elevated plasma GLP-1 levels compared to those in control rats. The effects of TQ were enhanced by treatment with sitagliptin and reduced by the injection of Ex 9–39 into the brain. In contrast, similar treatment with another antioxidant (either ascorbic acid or N-acetylcysteine) produced the same anorexic effect as TQ without changing the plasma GLP-1 levels in diabetic rats. Therefore, TQ attenuated hyperphagy while increasing plasma GLP-1 levels and had antioxidant-like effects.Conclusion: TQ increased endogenous GLP-1 levels to reduce hyperphagy in diabetic rats.

Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions.

The association between longitudinal changes in serum glucose level and longitudinal changes in [18F] Fluorodeoxyglucose-PET (FDG PET) measurements of Alzheimer's disease (AD) risk are unknown. To investigate whether variation in serum glucose levels across time are associated with changes in FDG PET measurements of cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer's disease (AD). Participants are a subset of a prospective cohort study investigating FDG PET, apolipoprotein E (APOE) ɛ4, and risk for AD which includes data from baseline, interim, and follow up visits over 4.4±1.0-years. An automated brain-mapping algorithm was utilized to characterize and compare associations between longitudinal changes in serum glucose levels and longitudinal changes in rCMRgl. This study included 80 adults aged 61.5±5 years, including 38 carriers and 42 non-carriers of the APOE ɛ4 allele. Longitudinal increases in serum glucose levels were associated with longitudinal CMRgl decline in the vicinity of parietotemporal, precuneus/posterior cingulate, and prefrontal brain regions preferentially affected by AD (p < 0.05, corrected for multiple comparisons). Findings remained significant when controlled for APOE ɛ4 status and baseline and advancing age. Additional studies are needed to clarify and confirm the relationship between longitudinal changes in peripheral glucose and FDG PET measurements of AD risk. Future findings will set the stage on the use of FDG PET in the evaluation of possible interventions that target risk factors for the development of AD.

Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)

AimsTo compare the efficacy on glycemic parameters between a 12-week administration of once-daily linagliptin and thrice-daily voglibose in Japanese patients with type 2 diabetes. MethodsIn a multi-center, randomized, parallel-group study, 382 patients with diabetes were randomized to the linagliptin group (n=192) or the voglibose group (n=190). A meal tolerance test was performed at weeks 0 and 12. Primary outcomes were the change from baseline to week 12 in serum glucose levels at 2h during the meal tolerance test, HbA1c levels, and serum fasting glucose levels, which were compared between the 2 groups. ResultsWhereas changes in serum glucose levels at 2h during the meal tolerance test did not differ between the groups, the mean change in HbA1c levels from baseline to week 12 in the linagliptin group (−0.5±0.5% [−5.1±5.4mmol/mol]) was significantly larger than in the voglibose group (−0.2±0.5% [−2.7±5.4mmol/mol]). In addition, there was significant difference in changes in serum fasting glucose levels (−0.51±0.95mmol/L in the linagliptin group vs. −0.18±0.92mmol/L in the voglibose group, P<0.001). The incidences of hypoglycemia, serious adverse events (AEs), and discontinuations due to AEs were low and similar in both groups. However, gastrointestinal AEs were significantly lower in the linagliptin group (1.05% vs. 5.85%; P=0.01). ConclusionsThese data suggested that linagliptin monotherapy had a stronger glucose-lowering effect than voglibose monotherapy with respect to HbA1c and serum fasting glucose levels, but not serum glucose levels 2h after the start of the meal tolerance test.

Investigation of the physiological, behavioral, and biochemical responses of cattle to restraint stress.

Stresses imposed on livestock have significant impact on their health and productivity as well as public perceptions of animal welfare. Understanding stress responses in livestock may help refine management procedures and facilitate selection of stress-tolerant animals. In this study, behavioral (chute entry order, chute behavior, and exit velocity), physiological (serum cortisol), and biochemical (kinome) responses were evaluated in cattle ( = 20) subjected to three 5-min restraint periods with weekly intervals. Correlations among stress responses were assessed across all animals as well as for subgroups ( = 4) representing animals consistently displaying a high and low extreme of serum cortisol responses. Across all animals, entry order ( = 0.006) and exit velocity ( = 0.023) were positively correlated with serum cortisol; however, these correlations were not consistently reproducible for the high and low serum cortisol responders. Kinome profiling of peripheral blood mononuclear cells revealed distinct signaling events between the high and low cortisol responders. In particular, kinome profiling revealed significant differences in carbohydrate metabolism and apoptosis that were independently validated. Furthermore, changes in serum glucose levels provided a reliable, inexpensive indicator of serum cortisol levels and often had greater predictive value than cortisol for stress-related behavioral responses. Serum cortisol levels displayed a pattern consistent with sensitization, whereas no habituation or sensitization was observed for serum glucose levels or behavioral responses. Collectively, this investigation provides insight into correlations among physiological, behavioral, and biochemical responses of cattle subjected to a brief restraint that may provide biomarkers for selection of stress-tolerant animals.

An Elevated Glycemic Gap is Associated with Adverse Outcomes in Diabetic Patients with Acute Myocardial Infarction.

Acute hyperglycemia is a frequent finding in patients presenting to the emergency department (ED) with acute myocardial infarction (AMI). The prognostic role of hyperglycemia in diabetic patients with AMI remains controversial. We retrospectively reviewed patients’ medical records to obtain demographic data, clinical presentation, major adverse cardiac events (MACEs), several clinical scores and laboratory data, including the plasma glucose level at initial presentation and HbA1c levels. The glycemic gap, which represents changes in serum glucose levels during the index event, was calculated from the glucose level upon ED admission minus the HbA1c-derived average glucose (ADAG). We enrolled 331 patients after the review of medical records. An elevated glycemic gap between admission serum glucose levels and ADAG were associated with an increased risk of mortality in patients. The glycemic gap showed superior discriminative power regarding the development of MACEs when compared with the admission glucose level. The calculation of the glycemic gap may increase the discriminative powers of established clinical scoring systems in diabetic patients presenting to the ED with AMI. In conclusion, the glycemic gap could be used as an adjunct parameter to assess the severity and prognosis of diabetic patients presenting with AMI. However, the usefulness of the glycemic gap should be further explored in prospective longitudinal studies.

Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer (在前列腺癌高风险的男性中补硒治疗对血糖水平没有影响)

Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Data were obtained from 699 men participating in a randomized double-blind placebo-controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400 μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed-effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium-supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8 h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200 μg/day (P = 0.98) and 400 μg/day (P = 0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature.

Abstract 3615: Does selenium supplementation increase serum glucose levels in men at high risk for prostate cancer.

Abstract Background: Current literature regarding the effect of selenium supplementation on risk of diabetes is inconclusive. Hence a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods: Data were obtained from 699 men participating in a randomized, double-blind, placebo-controlled Phase 3 clinical trial investigating the effect of two doses of selenium (200 and 400 μg/day) compared to placebo on incidence of prostate cancer. Subjects were followed every six months for up to five years. Serum glucose levels were obtained every six months. Mixed effects regression models were used to assess if rate of change of serum glucose levels was significantly different in the selenium supplemented groups as compared to placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results: Of the total 2893 glucose measurements, 734 were carried out when the subject had been fasting for ≥ 8 hours. The changes in serum glucose levels during the course of the trial were not statistically significantly different as compared to placebo for the selenium 200 μg/day (p = 0.88) or selenium 400 μg/day (p = 0.45) treatment groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion: These results do not support a relationship between selenium supplementation and risk of diabetes. Hence recommendations regarding selenium supplementation based on increased risk of diabetes seem premature. Citation Format: Amit M. Algotar, C H. Hsu, Steven P. Stratton. Does selenium supplementation increase serum glucose levels in men at high risk for prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3615. doi:10.1158/1538-7445.AM2013-3615

Effect of different dietary energy levels on physio-biochemical, endocrine changes and mRNA expression profile of leptin in goat (Capra hircus)

This study aims to assess the effect of different energy levels of restriction on physiological and genetic level adaptability. Eighteen adult nonpregnant does (average BW 33.56kg) were used in the present study. The ewes were divided into three groups, viz., GI (n=6; control), GII (n=6; 30% feed intake of control), GIII (n=6; 40% feed intake of control). The study was conducted for 40 days covering a period of two estrous cycles. Blood samples were collected every ten days interval. The parameters studied were allometric parameters (viz., body weight, and body condition) scoring and physiological responses (viz., respiration rate, pulse rate, and rectal temperature) biochemical parameters (glucose, albumin, creatinine, cholesterol), hormones (T3, T4, cortisol, leptin) and mRNA expression profile of leptin in peripheral blood mononuclear cells (PBMC). The nutritional stress significantly (P<0.05) affected most of the parameters. There was a significant (P<0.05) reduction in Body weight, Body condition score and. The physiological responses were significantly (P<0.05) affected. Among the biochemical parameters mean serum glucose first increased significantly (P<0.05) and then stabilized in GII whereas as there was no change in serum glucose levels in GIII. Serum albumin significantly (P<0.05) affected in late stages of study. There was no significant (P<0.05) changes in serum creatinine. Among hormonal parameters there was significant decrease in T3 in both the groups; T4 increased significantly in GII on 10th day and then stabilized whereas no changes was observed in GIII. Cortisol levels increased significantly (P<0.05) in both GII and GIII. There was a significant (P<0.05) reduction in serum leptin levels in GII but in GIII significant reduction was observed only 10th and 30th day of study. The mRNA expression was significantly (P<0.05) upregulated in GII on 30th day followed by a significant downregulation whereas in GIII significant (P<0.05) downregulation was only seen on 30th and 40th days. It can be concluded from our study that animals can maintain near physiological homeostasis even at 40% energy intake levels. The animals have innate physiological ability to survive periods of nutritional stress by adjusting leptin levels which are required for maintaining the physiological normalcy.

Olanzapine as an add-on treatment in migraine status: A randomized double-blind, placebo-controlled, pilot study

Background and Objectives: The authors assessed the effectiveness of olanzapine as an adjunctive treatment in migraine status. Methods: Randomized, double-blind, placebo-controlled study. Subjects consecutively admitted to a day program of tertiary referral (97 % women; age: 35.8 �} 11.8 yrs.) were assigned to olanzapine (n = 14, 5-10 mg/day) or placebo (n = 17), added to the standard neurological treatment during 4 days. Primary measures were the change in pain and the return to regular daily activities. Secondary and safety measures were the magnitude of sedation, constipation and glucose level changes. Results: No significant differences were observed in the overall analysis of the primary measures. However, change in pain significantly correlated with age in the olanzapine group (p = 0.03). In the . 40 year-old group, olanzapine (n = 5) displayed a significantly higher reduction in pain than placebo (n = 4) at days 1 (p = 0.048) and 3 (p = 0.045). No significant differences were observed in the change of serum glucose levels. Conclusions: Olanzapine was well tolerated and sedation was welcomed by most subjects. The positive effect in subjects aged . 40 years awaits replication.

No Effect of Selenium Supplementation on Serum Glucose Levels in Men with Prostate Cancer

Background Literature indicates a relationship between selenium supplementation and risk of diabetes. However, because these data are inconclusive, we investigated the effect of selenium supplementation on serum glucose levels in men with prostate cancer enrolled in a clinical trial testing of the effect of selenium on prostate cancer progression. Methods Subjects were randomized to receive placebo (n = 46), selenium 200 μg/day (n = 47), and selenium 800 μg/day (n = 47). Serum glucose levels were obtained every 6 months for up to 5 years. Longitudinal analysis was carried out to assess whether rate of change of serum glucose levels was significantly different in the selenium-supplemented groups as compared with placebo. Sensitivity analyses were performed to assess the robustness of findings. Results Changes in serum glucose levels during the course of the trial were not statistically significantly different as compared with placebo for the selenium 200 μg/day ( P = .56) or selenium 800 μg/day ( P = .91) treatment groups. Conclusion These results do not support a relationship between selenium supplementation and changes in serum glucose levels. Recommendations about selenium supplementation and risk of diabetes will require more definitive studies.

Risk assessment induced by knapsack or conventional motor sprayer on pesticides applicators and farm workers in cotton season

Fakous Province in the Sharkia Governorate constitutes one of the largest agricultural areas in Egypt. The majority of people in this province rely on subsistence agriculture. In the cotton cultivation season the continuous application of pesticides is commonly used to increase agricultural productivity, using different types of spraying equipment. In this study a cohort of 210 intensive agricultural pesticide applicators and farm workers from Sawada and Akyad Elkepplia villages in Fakous Province were assessed according to the type of spraying equipment they used. Conventional motor (300 l/feddan or 0.42 ha) and knapsack motor sprayer (20 l/feddan) were commonly used by farmers. Contamination on applicators was detected on head, body (thorax/abdomen) and legs at different percentages according to the spraying tools. The recorded results revealed that contamination with pesticides due to knapsack motor sprayers 0.76% on head, 4.8% on body and 5.8% on legs; however, conventional motor sprayers induce contamination of 3.6% on head, 23.7% on body and 29.1% on legs. Several criteria for estimating pesticide contamination by previous delivery systems were used. The most important reference biomarker was serum acetyl cholinesterase (AchE) depression. Sprayers showed changes in serum glucose levels as well as reduced erythrocytic glutathione levels (GSH). However, an increase in both total serum protein and albumin was recorded also, alongside elevation in lipid peroxidation biomarker malondialdehyde (MDA). Changes in serum biochemistry regarding enzymes reflecting cytotoxicity were also recorded, such as inhibition of alanine aminotransferase (ALT) and glutathione-S-transferase (GST). An increase in aspartate aminotransferase (AST) and glutathione reductase (GR) was observed particularly in conventional motor sprayers. Changes in enzymes activities found in this study are linked to the adverse health effects related to chronic pesticide toxicity that may lead to pathophysiological diseases, cancer or neurodegenerative disorders, which warrants further investigation.

Lack of Correlation Between Thiazide‐Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study

To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients. Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers. Community-based ambulatory population of 202 patients (age range 17-65 yrs) with a new diagnosis of hypertension, untreated hypertension, or known hypertension, who were previously treated with fewer than three antihypertensive drugs and had no evidence of cardiovascular disease or diabetes mellitus. Intervention. Monotherapy with oral hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks. Fasting serum glucose, serum potassium, and plasma insulin levels were obtained at baseline (before hydrochlorothiazide therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum glucose (mean +/- SD 3.42 +/- 10.38 mg/dl, p<0.0001) and plasma insulin (2.35 +/- 9.47 microU/ml, p<0.0001) levels, and a significant reduction in serum potassium level (0.30 +/- 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum glucose and potassium levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum potassium and plasma insulin levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum glucose levels did not differ significantly between patients maintaining serum potassium levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L. Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia.

Use of therapeutic responses to glucose replacement to predict glucose patterns in diabetic patients presenting with severe hypoglycaemia

The purpose of this study was to determine whether initial serum glucose levels, therapeutic responses to intravenous glucose replacement and changes in serum glucose levels over time could predict serum glucose patterns. The patients enrolled in this retrospective chart review had been previously diagnosed with diabetes mellitus and were later hospitalised for severe hypoglycaemia (SH). They were all admitted to the emergency department (ED) during a 4-year period between January 2003 and December 2006. Comparison of the therapeutic responses to glucose replacement according to the serum glucose patterns [categorised into recurrent hypoglycaemia (RH), overshoot hyperglycaemia (OH) and favourable groups] during the first 48 h was performed. Compared with the favourable group, therapeutic responses to glucose replacement were significantly lower in the RH group and higher in the OH group; the changes in serum glucose levels over time were also significantly lower in the RH group and higher in the OH group. Therapeutic responses to glucose replacement and changes in serum glucose levels over time can differentiate diabetic patients with RH and OH from those with favourable glucose patterns during the first 48 h after presentation in the ED with SH. We believe that a 'response-to-treatment' based strategy is useful in determining the ED disposition of diabetic patients presenting with SH.

7-O-Galloyl-D-sedoheptulose Is a Novel Therapeutic Agent against Oxidative Stress and Advanced Glycation Endproducts in the Diabetic Kidney

Diabetes is the leading cause of end-stage renal failure, since glucose-dependent metabolic factors are synergistically activated within the diabetic kidney. Accordingly, in Japan, there is much debate over the health benefits of natural therapies to reduce these risk factors. In our previous study, we reported that Cornus officinalis SIEB. et ZUCC. possessed an antidiabetic effect via ameliorating glucose-mediated metabolic disorders as well as aminoguanidine, an inhibitor of advanced glycation endproduct (AGE) formation, with a renoprotective effect. The aim of the present study was to investigate the effect of 7-O-galloyl-D-sedoheptulose (GS) against diabetic oxidative stress and AGE formation. Streptozotocin-induced diabetic rats were orally administered GS for 20 d, and the changes in serum glucose levels, as well as those of body weight every 10 d were evaluated. In addition, glucose, fluorescent AGE, methylglyoxal, glycolaldehyde (GA), and immunoblotting analyses for heme oxygenase-1, receptor for AGE, N(epsilon)-(carboxymethyl)lysine, N(epsilon)-(carboxyethyl)lysine, and GA-pyridine were performed in the kidney at the end of the experiment. The results obtained in this study demonstrated that 20 d of treatment with GS had beneficial effects on hypoglycemic and renal metabolic abnormalities, including renal glucose, oxidative stress, and AGE formation. Together, our data help to elucidate its potential therapeutic value against diabetic kidney disease.

Diabetic ketoacidosis increases extracellular levels of the major inducible 70-kDa heat shock protein

Objectives: Diabetic ketoacidosis (DKA) represents a metabolic stress whose treatment induces a systemic proinflammatory cytokine profile and accentuates life-threatening acute complications. The present study determined whether serum levels of the major inducible 70-kDa heat shock protein (Hsp72), a modulator of cytokine expression, were influenced by DKA and its treatment. Design and methods: Serum levels of Hsp72 and glucose were measured in five adolescents with type 1 diabetes mellitus (T1DM) prior to, during and following correction of severe DKA. Samples from nine relatively euglycemic T1DM patients served as controls. Results: DKA pre-treatment samples showed significant elevation in Hsp72 (40.8 ± 6.9 ng/ml) relative to euglycemic T1DM controls (33.6 ± 3.2 ng/ml) ( P < 0.05). Treatment resulted in a decline in Hsp72 to control levels within 24 h, with Hsp72 and glucose levels being tightly correlated ( r = 0.9258). Conclusion: Extracellular Hsp72 is increased by DKA, paralleling changes in serum glucose levels.

Implanon ® contraceptive implants: effects on carbohydrate metabolism

The objective of the study was to assess the possible differences in effects of Implanon ® and Norplant ® implants on carbohydrate metabolism. This is a 2-year open randomized study of 80 implant (Implanon and Norplant) acceptors. Oral glucose tolerance test (OGTT) was performed before implant insertion and at 6, 12, and 24 months after implant insertion. Glycosylated hemoglobin A 1C was measured in fasting samples and plasma samples during OGTT were tested for glucose and insulin levels. There was a significant increase in the area under the curve for both glucose and insulin during OGTT within each group with increasing duration of use. However, there was no significant change in the fasting plasma glucose values. There was no significant difference in the carbohydrate parameters between the two groups during implant use, except for a minimal but statistically significant rise in fasting glycosylated hemoglobin A 1C levels at 24 months in the Implanon group. Both implants appear to induce mild insulin resistance but no significant change in serum glucose levels. These alterations in carbohydrate metabolism should have no clinical significance in healthy women.